Google
INMB — INMUNE BIO INC (Healthcare >> Biotechnology)
INMB FAQ
What is INMB's ROE?
INMUNE BIO INC reports a Return on Equity (ROE) of -211.99%.
What is INMB's dividend yield?
INMUNE BIO INC offers a dividend yield of 0.00%.
What is INMB's Deepscope Quality Score?
Deepscope rates INMB's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy INMB?
Deepscope's AI Timing Score for INMB is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does INMB belong to?
INMUNE BIO INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.32
Price
-0.10
(-7.04%)
Day Change
|
|
|---|
INMB, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.32 |
| PBV / Sector |
1.92 / 4.48
|
| Earning Per Share | -1.45 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.83 M
GREAT
|
| Average 1W Daily Value |
0.60 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:24:14 |
| Symbol | INMB |
| Name | INMUNE BIO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 26.59 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 37.75 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432
Phone: 561 710 0512
Website: https://www.inmunebio.com
Sector: Healthcare >> Biotechnology
Description: INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
